INSILICO (03696) and Servier's AI R&D collaboration achieves early drug discovery milestone, triggering a milestone payment.

INSILICO (03696) announces that the company has achieved an early drug discovery milestone in its multi-year artificial intelligence (AI)-driven drug discovery collaboration with Servier (an independent international pharmaceutical group managed by a foundation). This multi-year R&D collaboration, first announced in early 2026, has a total value of up to US$888 million, including US$32 million in upfront and near-term R&D milestone payments. Under the collaboration, the two parties have launched two independent R&D projects in oncology based on INSILICO's proprietary end-to-end AI platform Pharma.AI. Both projects have now completed target nomination. After successfully meeting pre-defined project criteria, INSILICO has officially achieved the early drug discovery milestone for the first of the two R&D projects, triggering a milestone payment of an undisclosed amount from Servier to INSILICO.